Nailed a Job Interview? Prepare to Wait for an Offer
The improving job market may have more people looking for jobs, but the experience of doing so has gotten rougher.
Job seekers last year had to wait an average of 23 days after an initial interview to find out whether they gotten the job or not. That’s nearly twice the 13 days the interview process took in 2010, according to a new report from Glassdoor.com.
It’s also far longer than the global average of just under four days. Part of the reason for the extended process in the United States is an increase in the use of background checks, skills tests, and drug tests.
Related: The Top 10 Hiring Myths
Police officers faced the longest hiring process (128 days), followed by patent examiners (88 days), and assistant professors (58.7) days.
“Right now hiring delays can represent money left on the table both for workers and employers,” Glassdoor Chief Economist Andrew Chamberlain said in a statement.
When employers can’t find the right worker, vacancies stay open for an average of two months, according to a separate report last spring by CareerBuilder. A fifth of employers said those vacancies stay open for more than six months, on average.
Those employers said the extended vacancies led to lower morale, a reduction in productivity, and declines in customer service.
Lower-skilled jobs tended to get filled most quickly. Entry-level marketing jobs were filled most quickly (four days), followed by entry-level sales (five days), and servers and bartenders (six days), according to the GlassDoor report.
Chart of the Day: Boosting Corporate Tax Revenues
The leading candidates for the Democratic presidential nomination have all proposed increasing taxes on corporations, including raising income tax rates to levels ranging from 25% to 35%, up from the current 21% imposed by the Republican tax cuts in 2017. With Bernie Sanders leading the way at $3.9 trillion, here’s how much revenue the higher proposed corporate taxes, along with additional proposed surtaxes and reduced tax breaks, would generate over a decade, according to calculations by the right-leaning Tax Foundation, highlighted Wednesday by Bloomberg News.
Chart of the Day: Discretionary Spending Droops
The federal government’s total non-defense discretionary spending – which covers everything from education and national parks to veterans’ medical care and low-income housing assistance – equals 3.2% of GDP in 2020, near historic lows going back to 1962, according to an analysis this week from the Center on Budget and Policy Priorities.
Chart of the Week: Trump Adds $4.7 Trillion in Debt
The Committee for a Responsible Federal Budget estimated this week that President Trump has now signed legislation that will add a total of $4.7 trillion to the national debt between 2017 and 2029. Tax cuts and spending increases account for similar portions of the projected increase, though if the individual tax cuts in the 2017 Republican overhaul are extended beyond their current expiration date at the end of 2025, they would add another $1 trillion in debt through 2029.
Chart of the Day: The Long Decline in Interest Rates
Are interest rates destined to move higher, increasing the cost of private and public debt? While many experts believe that higher rates are all but inevitable, historian Paul Schmelzing argues that today’s low-interest environment is consistent with a long-term trend stretching back 600 years.
The chart “shows a clear historical downtrend, with rates falling about 1% every 60 years to near zero today,” says Bloomberg’s Aaron Brown. “Rates do tend to revert to a mean, but that mean seems to be declining.”
Chart of the Day: Drug Price Plans Compared
Lawmakers are considering three separate bills that are intended to reduce the cost of prescription drugs. Here’s an overview of the proposals, from a series of charts produced by the Kaiser Family Foundation this week. An interesting detail highlighted in another chart: 88% of voters – including 92% of Democrats and 85% of Republicans – want to give the government the power to negotiate prices with drug companies.
